Evidence map›Paper›PMID 36652176›Full record

ArticleAdvances in therapy2023

Complement C3 Facilitates Stratification of Stages of Chronic Hepatitis B and Signifies Development of Acute-on-Chronic Liver Failure in Acute Decompensated Cirrhosis.

Chong Chen, Zhu Yuan, Weixia Li, Ling Fei, Liujuan Ji, Qin Huang, Shuye Zhang, Liang Chen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The C3/C3aR pathway exacerbates acetaminophen-induced mouse liver injury via upregulating podoplanin on the macrophage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Review
  4. Role of Complement in Liver Diseases.Seminars in liver disease · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chong Chen *Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.ORCID http://orcid.org/0000-0002-6653-9901
Zhu Yuan *Department of Endocrinology, Jinshan Branch of Shanghai Sixth People's Hospital, Shanghai, 201599, China.
Weixia LiDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Ling FeiDepartment of Hepatology, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jin-Shan District, Shanghai, 201508, China.
Liujuan JiDepartment of Severe Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Qin HuangDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Shuye Zhang *Clinical Center for BioTherapy, Zhongshan Hospital, Fudan University, No.180 Fengling Road, Xuhui District, Shanghai, 200031, China. shuye_zhang@fudan.edu.cn.
Liang Chen *Department of Hepatology, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jin-Shan District, Shanghai, 201508, China. chenliang@shphc.org.cn.
Shanghai Public Health Clinical Center · CNFudan University · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with chronic hepatitis B (CHB) have a dynamic disease process and risk of end-stage liver disease. It is critical to unambiguously differentiate the stages of the disease and focus on therapy prior to onset of an irreversible clinical endpoint.

methodsWe retrospectively analyzed a wide range of CHB patients at different stages. The predictive power of serum complement component 3 (C3) levels for the development of acute-on-chronic liver failure (ACLF) in patients with decompensated cirrhosis was established and validated.

resultsThe decrease in serum C3 levels paralleled the severity of diseases related to hepatitis B virus. Patients with decompensated cirrhosis who developed ACLF had significantly lower serum C3 levels than others on admission (0.50 vs. 0.80 g/L, P < 0.001). Data analysis also revealed that low serum C3 was a significant risk factor for developing ACLF (hazard ratio = 0.32, P < 0.01). The area under the receiver operating characteristic curve (auROC) for serum C3 levels that predicted the development of ACLF in patients with decompensated cirrhosis was 0.90, which had sensitivity and specificity of 88.2% and 88.7%, respectively. A similar result was observed in the validation set (auROC = 0.86 for predicting development of ACLF in patients with decompensated cirrhosis).

conclusionsSerum C3 levels are valuable in assessing the severity of CHB-related stages. Low C3 levels signifies the development of ACLF in patients with decompensated cirrhosis.

Indexed as

Acute-On-Chronic Liver FailureHepatitis B, ChronicComplement C3HumansLiver CirrhosisPrognosisRetrospective StudiesComplement C3Acute-on-chronic liver failureCirrhosisComplement C3Hepatitis B virus

Identifiers

PMID36652176
PMCPMC9848025
OpenAlexW4317213399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.